Pioneering Pain Management: High-Frequency Electrical Stimulation Devices

By HEOR Staff Writer

October 27, 2023

The Current Opioid Crisis and the Treatment of Post-Caesarean Pain

Systemic opioids are the medication that is utilised the most frequently, despite the fact that pain management following a caesarean delivery is a complicated issue. Having said that, this method is not without its flaws. The overprescription of opioids is a key cause, and it is estimated that 1.2 million of the caesarean births performed annually in the United States result in the disposal of 12 million unneeded tablets. There is a high likelihood that these unused tablets will be abused, which will contribute to the continuing opioid problem.

 

A Novel Technique for the Management of Pain

A recent study found that devices that use high-frequency electrical stimulation could be an effective solution to the problem. According to the findings of the study, women who had caesarean deliveries followed by transcutaneous treatment using a high-frequency electrical stimulation device required around 47 percent less opioid analgesic medication while they were in the hospital. In addition, these individuals reported levels of discomfort that were comparable to those reported by patients who had used a sham device.

High-frequency electrical stimulation devices

This breakthrough has the potential to constitute a key step towards lowering the use of opioids, avoiding overprescribing, and preventing dependence from developing. Because it is estimated that 36,000 to 72,000 people in the United States develop a dependence on opioids each year after having a caesarean delivery, finding effective measures to reduce opioid use continues to be a public health priority.

Reference url

Recent Posts

Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic R&D

By João L. Carapinha

February 26, 2026

Novartis drug discovery innovation is transforming global health through the Biomedical Research group's shift from siloed efforts to an integrated, patient-centric model targeting high-burden diseases in low- and middle-income countries (LMICs). Under Manju Ujjini, Head of Lead Discovery, key mi...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in ARTISTRY Trials
BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) an...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per month across key doses, effective January 1, 2027....